Retraction: Influence of long-term continuous intravenous administration of pentoxifylline on endothelial-related coagulation in critically ill patients (Critical Care Medicine (1996) 24 (940-946) DOI: 10.1097/00003246-199606000-00011);Influence of long-term continuous intravenous administration of pentoxifylline on endothelial-related coagulation in critically ill patients

Critical Care Medicine

Volumn 24, Issue 6, 1996, Pages 940-946

  Boldt, Joachim ^a   Müller, Matthias ^a   Heyn, Stephan ^a   Welters, Ingeborg ^a   Hempelmann, Gunter ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

coagulation; critically ill; endothelium; inflammation; pentoxifylline; protein C; protein S; sepsis; thrombomodulin; trauma

Indexed keywords

ADRENALIN; ANTITHROMBIN; FIBRINOGEN; HEMOGLOBIN; HEPARIN; NORADRENALIN; PENTOXIFYLLINE; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; ENDOTHELIUM INJURY; FEMALE; HEMODYNAMICS; HOSPITALIZATION; HUMAN; INJURY; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE BLIND PROCEDURE;

EID: 0030006971     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000005911     Document Type: Erratum

References (38)

1. Bone RC: Sepsis and coagulation - An important link. Chest 1992; 101:594-595
2. Lorente JA, Garcia-Frade J, Landin L, et al: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103:1536-1542
3. Brenner BM, Troy JL, Ballermann B: Endothelium-dependent vascular responses. J Clin Invest 1989; 84: 1373-1378
4. Vincent J-L, Preiser JC, Frieman G, et al: Endothelial cell function in the critically ill. In: Sepsis. Update in Intensive Care and Emergency Medicine. Vol VIII. Reinhart K, Eyrich K, Sprung C (Eds). Berlin, Heidelberg, New York, Springer-Verlag, 1994, pp 174-180
5. Williams TJ, Hellewell PG: Endothelial cell biology. Am Rev Respir Dis 1992; 146:S45-S50
6. Esmon D, Esposito C, Gerlach H, et al: Endothelium and regulation of coagulation. Diabetes Care 1991; 14(Suppl 2): 160-166
7. Dittman WA: Thrombomodulin. Biological and cardiovascular applications. Trends Cardiovasc Med 1991; 1:331-336
8. Mann KG, Krishnaswamy S, Lawson JH: Surface-dependent hemostasis. Semin Hematol 1992; 29:213-226
9. Esmon NL: Thrombomodulin. Prog Hemost Thromb 1989; 9:29-55
10. Clouse LH, Comp PC: The regulation of hemostasis: The protein C system. N Engl J Med 1986; 15:1298-1303
11. Sakata Y, Loskutoff DJ, Gladstone C, et al: Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor. Blood 1986; 68:1218-1222
12. Boffa MC, Karochkine M, Berad M: Plasma thrombomodulin as a marker of endothelium damage. Nouv Rev Fr Hematol 1991; 33:529-530
13. Takano S, Kimura S, Ohdama S, et al: Plasma thrombomodulin in health and diseases. Blood 1990; 76:2024-2029
14. Asakura H, Jokaji H, Saito M, et al: Plasma levels of soluble thrombomodulin increase in cases of disseminated intravascular coagulation with organ failure. Am J Hematol 1991; 38:281-287
15. Uchiyama H, Hiraishi S, Ishii H, et al: Plasma thrombomodulin is originated by damage of endothelial cell. Thromb Haemost 1989; 62:276-280
16. Moore KL, Andreoli SP, Esmon CT, et al: Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79:124-130
17. Bevilacqua MP, Pober JS, Majeua GR, et al: Interleukin 1 (IL-1) indices biosynthesis and cellular surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160:618-623
18. Dorman T, Breslow MJ: Altered immune function after trauma and hemorrhage: What does it all mean? Crit Care Med 1994; 22:1069-1070
19. Suffredini AF: Current prospects for the treatment of clinical sepsis. Crit Care Med 1994; 22:S12-S14
20. Ward A, Clissold SP: Pentoxifylline - A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97
21. Samlaska CP, Winfield EA: Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-621
22. Baker SP, O'Neill B: The injury severity score: An update. J Trauma 1976; 16:882-888
23. Members of the American College of Chest Physicians/Society of Critical Care Medicine Conference Committee: American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
24. Webb AR, Mythen MG, Jacobson D, et al: Maintaining blood flow in the extracorporeal circuit: Haemostasis and anticoagulation. Intensive Care Med 1995; 21:84-93
25. Ishii H, Uchiyama H, Kazama M: Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65:618-623
26. Hesselvik JF, Malm J, Dahlbeck B, et al: Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991; 65:126-129
27. Steeb GD, Wilson MA, Garrison RN: Pentoxifylline preserves small intestine microvascular blood flow during bacteremia. Surgery 1992; 112:756-764
28. Sigurdsson GH, Youssef H: Effects of pentoxifylline on hemodynamics, gas exchange and multiple organ platelet sequestration in experimental endotoxic shock. Acta Anaesthesiol Scand 1993; 37:396-403
29. Brody JI, Pickering NJ, Fink GB: Abnormalities of thrombomodulin and tissue plasminogen activator in occluded aortocoronary grafts detected by immunohistochemistry. Trans Assoc Am Physicians 1988; 101:79-87
30. Bessler H, Gilgal R, Djaldetti M, et al: Effects of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 1986; 40:747-754
31. Archipoff G, Beretz A, Bartha K, et al: Role of cyclic AMP in promoting the thromboresistance of human endothelial cells by enhancing thrombomodulin and decreasing tissue factor activities. Br J Pharmacol 1993; 109:18-28
32. 2 in healthy volunteers. Prostaglandins Leukotr Med 1986; 22:191-200
33. Schönharting M, Musikic P, Müller R: The hemorheological and antithrombotic potential of pentoxifylline (Trental). Pharmatherapeutica 1988; 5:159-169
34. Levi M, ten Cate H, Bauer KE, et al: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-issue factor antibody in chimpanzees. J Clin Invest 1994; 93:114-120
35. Ohdama S, Takano S, Ohashi K, et al: Pentoxifylline prevents tumor necrosis factor-induced suppression of endothelial cell surface thrombomodulin. Thromb Res 1991; 62:745-755
36. Bassi DG, Foitzik T, Rattner DW, et al: Failure of pentoxifylline to ameliorate severe acute pancreatitis in the rat: Results of a prospective, randomized, controlled study. Crit Care Med 1994; 22:1960-1963
37. Santucci L, Fiorucci S, Giansanti M, et al: Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: Role of tumor necrosis factor alpha. Gut 1994; 35:909-915
38. Lechner AJ, Rouben LR, Potthoff LH, et al: Effects of pentoxifylline on tumor necrosis production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock. Circ Shock 1993; 39:306-315